Results 91 to 100 of about 17,623 (143)

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

EVALUATION OF THE MINIMUM INHIBITORY CONCENTRATION OF MEROPENEM AND NEW THERAPEUTIC OPTIONS FOR SERRATIA MARCESCENS AND MORGANELLACEAE ENTEROBACTERALES WITH REDUCED SUSCEPTIBILITY TO MEROPENEM

Brazilian Journal of Infectious Diseases
Introduction/Objective: Serratia marcescens and Enterobacterales of the Morganellaceae family are associated with infections in different sites and exhibit an expected phenotype of resistance to several antimicrobials, making therapeutic options very ...
Lívia Medeiros, Eduarda Castro Oliveira, Mariana Preussler Mott, Bruno Watanabe, Rodrigo Minuto Paiva, Larissa Lutz   +5 more
doaj   +1 more source

Meropenem / Meropenem-vaborbactam

, 2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms,
Peleg, A. Y., Harris, P.
core   +1 more source

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V).
Jonathan C. Cho, Monika T. Zmarlicka, Joe Pardo, Kristy M. Shaeer   +3 more
core   +1 more source

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties

Transplant International
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi, Andrea Lombardi, Davide Mangioni, Giulia Viero, Laura Alagna, Giulia Renisi, Paola Saltini, Alessandra Bandera, Alessandra Bandera   +8 more
doaj   +1 more source

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Debora Rubio-Aparicio, Michael N. Dudley, Ruslan Tsivkovski, David C. Griffith, Dongxu Sun, Kirk Nelson, Olga Lomovskaya   +6 more
core   +1 more source

Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019–2023)

Antibiotics
Objective: To evaluate the antimicrobial susceptibility of Enterobacterales isolated from patients with intra-abdominal infections (IAI) in United States (US) medical centres.
Helio S. Sader, John H. Kimbrough, Marisa L. Winkler, Rodrigo E. Mendes, Mariana Castanheira   +4 more
doaj   +1 more source

Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals

Journal of Global Antimicrobial Resistance
Objectives: Enterobacterales isolates producing β-lactamases are widespread and threaten the use of β-lactams. This study evaluated the activity of aztreonam-avibactam and comparator antimicrobial agents against Enterobacterales isolates producing common
Lalitagauri M Deshpande, Timothy B Doyle, Helio S Sader, Mariana Castanheira   +3 more
doaj   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]

Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M, Mazzei, P, Bokesch, PM, Bradley, JS, Capriati, A, Fornari, C, Habboubi, N, Auriol, FK, Borella, E, Vallespir, BP, Magalhaes, P, Hoover, R, Piana, C, Arrieta, A, Pasqua, OD   +14 more
core   +1 more source